Intrinsic value of Seattle Genetics, Inc. - SGEN

Previous Close

$68.50

  Intrinsic Value

$1.56

stock screener

  Rating & Target

str. sell

-98%

Previous close

$68.50

 
Intrinsic value

$1.56

 
Up/down potential

-98%

 
Rating

str. sell

We calculate the intrinsic value of SGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 11.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  34.60
  31.64
  28.98
  26.58
  24.42
  22.48
  20.73
  19.16
  17.74
  16.47
  15.32
  14.29
  13.36
  12.52
  11.77
  11.09
  10.48
  9.94
  9.44
  9.00
  8.60
  8.24
  7.91
  7.62
  7.36
  7.12
  6.91
  6.72
  6.55
  6.39
Revenue, $m
  882
  1,161
  1,497
  1,895
  2,357
  2,887
  3,486
  4,154
  4,891
  5,696
  6,569
  7,507
  8,510
  9,576
  10,703
  11,891
  13,137
  14,443
  15,807
  17,229
  18,711
  20,252
  21,855
  23,521
  25,253
  27,052
  28,922
  30,866
  32,887
  34,990
Variable operating expenses, $m
  1,197
  1,568
  2,014
  2,542
  3,156
  3,859
  4,653
  5,540
  6,517
  7,586
  8,717
  9,962
  11,293
  12,708
  14,203
  15,779
  17,434
  19,166
  20,976
  22,863
  24,829
  26,875
  29,002
  31,213
  33,510
  35,898
  38,380
  40,959
  43,642
  46,432
Fixed operating expenses, $m
  17
  18
  18
  19
  19
  19
  20
  20
  21
  21
  22
  22
  23
  23
  24
  24
  25
  25
  26
  26
  27
  27
  28
  29
  29
  30
  31
  31
  32
  33
Total operating expenses, $m
  1,214
  1,586
  2,032
  2,561
  3,175
  3,878
  4,673
  5,560
  6,538
  7,607
  8,739
  9,984
  11,316
  12,731
  14,227
  15,803
  17,459
  19,191
  21,002
  22,889
  24,856
  26,902
  29,030
  31,242
  33,539
  35,928
  38,411
  40,990
  43,674
  46,465
Operating income, $m
  -333
  -425
  -535
  -666
  -817
  -991
  -1,187
  -1,406
  -1,647
  -1,911
  -2,170
  -2,477
  -2,806
  -3,155
  -3,524
  -3,913
  -4,321
  -4,748
  -5,195
  -5,660
  -6,145
  -6,650
  -7,175
  -7,720
  -8,287
  -8,876
  -9,488
  -10,125
  -10,787
  -11,475
EBITDA, $m
  -281
  -364
  -465
  -585
  -723
  -882
  -1,061
  -1,261
  -1,482
  -1,723
  -1,984
  -2,265
  -2,565
  -2,884
  -3,221
  -3,576
  -3,949
  -4,340
  -4,748
  -5,173
  -5,616
  -6,077
  -6,557
  -7,055
  -7,573
  -8,111
  -8,671
  -9,252
  -9,856
  -10,485
Interest expense (income), $m
  0
  0
  4
  10
  16
  23
  32
  42
  54
  66
  80
  95
  112
  130
  149
  169
  190
  212
  236
  261
  286
  313
  341
  370
  401
  432
  465
  499
  534
  571
  609
Earnings before tax, $m
  -333
  -429
  -545
  -682
  -841
  -1,023
  -1,229
  -1,460
  -1,714
  -1,991
  -2,265
  -2,589
  -2,935
  -3,303
  -3,692
  -4,103
  -4,533
  -4,984
  -5,455
  -5,947
  -6,459
  -6,992
  -7,545
  -8,121
  -8,720
  -9,341
  -9,987
  -10,659
  -11,358
  -12,084
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -333
  -429
  -545
  -682
  -841
  -1,023
  -1,229
  -1,460
  -1,714
  -1,991
  -2,265
  -2,589
  -2,935
  -3,303
  -3,692
  -4,103
  -4,533
  -4,984
  -5,455
  -5,947
  -6,459
  -6,992
  -7,545
  -8,121
  -8,720
  -9,341
  -9,987
  -10,659
  -11,358
  -12,084

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,774
  2,335
  3,012
  3,812
  4,743
  5,809
  7,014
  8,358
  9,840
  11,461
  13,217
  15,105
  17,123
  19,268
  21,536
  23,925
  26,434
  29,060
  31,804
  34,666
  37,647
  40,749
  43,974
  47,326
  50,810
  54,430
  58,193
  62,104
  66,171
  70,402
Adjusted assets (=assets-cash), $m
  1,774
  2,335
  3,012
  3,812
  4,743
  5,809
  7,014
  8,358
  9,840
  11,461
  13,217
  15,105
  17,123
  19,268
  21,536
  23,925
  26,434
  29,060
  31,804
  34,666
  37,647
  40,749
  43,974
  47,326
  50,810
  54,430
  58,193
  62,104
  66,171
  70,402
Revenue / Adjusted assets
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
Average production assets, $m
  232
  305
  394
  498
  620
  759
  917
  1,092
  1,286
  1,498
  1,728
  1,974
  2,238
  2,518
  2,815
  3,127
  3,455
  3,798
  4,157
  4,531
  4,921
  5,326
  5,748
  6,186
  6,641
  7,115
  7,606
  8,118
  8,649
  9,202
Working capital, $m
  24
  31
  40
  51
  64
  78
  94
  112
  132
  154
  177
  203
  230
  259
  289
  321
  355
  390
  427
  465
  505
  547
  590
  635
  682
  730
  781
  833
  888
  945
Total debt, $m
  79
  177
  295
  434
  596
  781
  991
  1,225
  1,483
  1,765
  2,070
  2,399
  2,750
  3,123
  3,518
  3,934
  4,370
  4,827
  5,305
  5,803
  6,321
  6,861
  7,422
  8,005
  8,612
  9,241
  9,896
  10,577
  11,284
  12,021
Total liabilities, $m
  309
  406
  524
  663
  825
  1,011
  1,220
  1,454
  1,712
  1,994
  2,300
  2,628
  2,979
  3,353
  3,747
  4,163
  4,599
  5,056
  5,534
  6,032
  6,551
  7,090
  7,651
  8,235
  8,841
  9,471
  10,126
  10,806
  11,514
  12,250
Total equity, $m
  1,465
  1,929
  2,488
  3,149
  3,918
  4,799
  5,793
  6,903
  8,128
  9,467
  10,917
  12,477
  14,144
  15,915
  17,789
  19,762
  21,834
  24,004
  26,270
  28,634
  31,096
  33,658
  36,322
  39,091
  41,969
  44,959
  48,067
  51,298
  54,657
  58,152
Total liabilities and equity, $m
  1,774
  2,335
  3,012
  3,812
  4,743
  5,810
  7,013
  8,357
  9,840
  11,461
  13,217
  15,105
  17,123
  19,268
  21,536
  23,925
  26,433
  29,060
  31,804
  34,666
  37,647
  40,748
  43,973
  47,326
  50,810
  54,430
  58,193
  62,104
  66,171
  70,402
Debt-to-equity ratio
  0.050
  0.090
  0.120
  0.140
  0.150
  0.160
  0.170
  0.180
  0.180
  0.190
  0.190
  0.190
  0.190
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
  0.210
  0.210
  0.210
  0.210
  0.210
  0.210
Adjusted equity ratio
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826
  0.826

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -333
  -429
  -545
  -682
  -841
  -1,023
  -1,229
  -1,460
  -1,714
  -1,991
  -2,265
  -2,589
  -2,935
  -3,303
  -3,692
  -4,103
  -4,533
  -4,984
  -5,455
  -5,947
  -6,459
  -6,992
  -7,545
  -8,121
  -8,720
  -9,341
  -9,987
  -10,659
  -11,358
  -12,084
Depreciation, amort., depletion, $m
  52
  60
  70
  81
  94
  109
  126
  145
  166
  189
  186
  212
  241
  271
  303
  336
  372
  408
  447
  487
  529
  573
  618
  665
  714
  765
  818
  873
  930
  989
Funds from operations, $m
  -281
  -369
  -475
  -600
  -747
  -914
  -1,103
  -1,315
  -1,548
  -1,803
  -2,079
  -2,377
  -2,694
  -3,032
  -3,390
  -3,766
  -4,162
  -4,576
  -5,008
  -5,460
  -5,930
  -6,419
  -6,927
  -7,456
  -8,005
  -8,576
  -9,170
  -9,786
  -10,428
  -11,095
Change in working capital, $m
  6
  8
  9
  11
  12
  14
  16
  18
  20
  22
  24
  25
  27
  29
  30
  32
  34
  35
  37
  38
  40
  42
  43
  45
  47
  49
  50
  52
  55
  57
Cash from operations, $m
  -287
  -376
  -484
  -611
  -759
  -928
  -1,120
  -1,333
  -1,568
  -1,825
  -2,103
  -2,402
  -2,721
  -3,061
  -3,420
  -3,798
  -4,195
  -4,611
  -5,045
  -5,498
  -5,970
  -6,460
  -6,971
  -7,501
  -8,052
  -8,625
  -9,220
  -9,839
  -10,482
  -11,152
Maintenance CAPEX, $m
  -19
  -25
  -33
  -42
  -54
  -67
  -82
  -99
  -117
  -138
  -161
  -186
  -212
  -241
  -271
  -303
  -336
  -372
  -408
  -447
  -487
  -529
  -573
  -618
  -665
  -714
  -765
  -818
  -873
  -930
New CAPEX, $m
  -59
  -73
  -88
  -105
  -122
  -139
  -157
  -176
  -194
  -212
  -230
  -247
  -264
  -280
  -296
  -312
  -328
  -343
  -359
  -374
  -390
  -405
  -422
  -438
  -455
  -473
  -492
  -511
  -532
  -553
Cash from investing activities, $m
  -78
  -98
  -121
  -147
  -176
  -206
  -239
  -275
  -311
  -350
  -391
  -433
  -476
  -521
  -567
  -615
  -664
  -715
  -767
  -821
  -877
  -934
  -995
  -1,056
  -1,120
  -1,187
  -1,257
  -1,329
  -1,405
  -1,483
Free cash flow, $m
  -365
  -475
  -605
  -758
  -934
  -1,134
  -1,359
  -1,607
  -1,879
  -2,175
  -2,493
  -2,835
  -3,198
  -3,582
  -3,987
  -4,413
  -4,859
  -5,326
  -5,812
  -6,319
  -6,847
  -7,395
  -7,965
  -8,557
  -9,173
  -9,812
  -10,477
  -11,168
  -11,887
  -12,635
Issuance/(repayment) of debt, $m
  79
  98
  118
  139
  162
  186
  210
  234
  258
  282
  306
  329
  351
  373
  395
  416
  436
  457
  477
  498
  519
  540
  561
  583
  606
  630
  655
  681
  708
  736
Issuance/(repurchase) of shares, $m
  710
  893
  1,104
  1,343
  1,610
  1,904
  2,224
  2,569
  2,938
  3,330
  3,715
  4,149
  4,602
  5,074
  5,566
  6,076
  6,605
  7,154
  7,722
  8,311
  8,921
  9,553
  10,209
  10,890
  11,597
  12,332
  13,095
  13,890
  14,717
  15,579
Cash from financing (excl. dividends), $m  
  789
  991
  1,222
  1,482
  1,772
  2,090
  2,434
  2,803
  3,196
  3,612
  4,021
  4,478
  4,953
  5,447
  5,961
  6,492
  7,041
  7,611
  8,199
  8,809
  9,440
  10,093
  10,770
  11,473
  12,203
  12,962
  13,750
  14,571
  15,425
  16,315
Total cash flow (excl. dividends), $m
  424
  516
  616
  724
  837
  955
  1,075
  1,196
  1,317
  1,437
  1,527
  1,643
  1,756
  1,866
  1,973
  2,078
  2,182
  2,285
  2,387
  2,490
  2,593
  2,698
  2,806
  2,916
  3,031
  3,149
  3,273
  3,402
  3,538
  3,681
Retained Cash Flow (-), $m
  -710
  -893
  -1,104
  -1,343
  -1,610
  -1,904
  -2,224
  -2,569
  -2,938
  -3,330
  -3,715
  -4,149
  -4,602
  -5,074
  -5,566
  -6,076
  -6,605
  -7,154
  -7,722
  -8,311
  -8,921
  -9,553
  -10,209
  -10,890
  -11,597
  -12,332
  -13,095
  -13,890
  -14,717
  -15,579
Prev. year cash balance distribution, $m
  186
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -100
  -377
  -487
  -619
  -772
  -949
  -1,149
  -1,373
  -1,621
  -1,893
  -2,188
  -2,506
  -2,846
  -3,209
  -3,593
  -3,998
  -4,423
  -4,869
  -5,335
  -5,821
  -6,328
  -6,855
  -7,404
  -7,974
  -8,567
  -9,182
  -9,822
  -10,487
  -11,179
  -11,898
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -96
  -345
  -424
  -510
  -599
  -689
  -776
  -858
  -931
  -992
  -1,039
  -1,069
  -1,082
  -1,077
  -1,055
  -1,016
  -962
  -897
  -821
  -740
  -655
  -569
  -485
  -406
  -333
  -268
  -211
  -162
  -122
  -90
Current shareholders' claim on cash, %
  93.0
  86.8
  81.4
  76.7
  72.4
  68.5
  65.0
  61.8
  58.9
  56.3
  53.8
  51.6
  49.4
  47.5
  45.6
  43.9
  42.2
  40.7
  39.2
  37.9
  36.5
  35.3
  34.1
  32.9
  31.8
  30.8
  29.8
  28.8
  27.9
  27.0

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

FINANCIAL RATIOS  of  Seattle Genetics, Inc. (SGEN)

Valuation Ratios
P/E Ratio -69.6
Price to Sales 23.3
Price to Book 15.4
Price to Tangible Book
Price to Cash Flow -100.4
Price to Free Cash Flow -77.9
Growth Rates
Sales Growth Rate 24%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 115.4%
Cap. Spend. - 3 Yr. Gr. Rate 4.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -16.2%
Ret/ On Assets - 3 Yr. Avg. -16.7%
Return On Total Capital -21.2%
Ret/ On T. Cap. - 3 Yr. Avg. -27.5%
Return On Equity -21.2%
Return On Equity - 3 Yr. Avg. -27.5%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 90%
Gross Margin - 3 Yr. Avg. 89.5%
EBITDA Margin -29.2%
EBITDA Margin - 3 Yr. Avg. -27.5%
Operating Margin -34.2%
Oper. Margin - 3 Yr. Avg. -32.3%
Pre-Tax Margin -33.5%
Pre-Tax Margin - 3 Yr. Avg. -31.9%
Net Profit Margin -33.5%
Net Profit Margin - 3 Yr. Avg. -31.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

SGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SGEN stock intrinsic value calculation we used $655 million for the last fiscal year's total revenue generated by Seattle Genetics, Inc.. The default revenue input number comes from 0001 income statement of Seattle Genetics, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SGEN stock valuation model: a) initial revenue growth rate of 34.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for SGEN is calculated based on our internal credit rating of Seattle Genetics, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Seattle Genetics, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SGEN stock the variable cost ratio is equal to 136.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $17 million in the base year in the intrinsic value calculation for SGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Seattle Genetics, Inc..

Corporate tax rate of 27% is the nominal tax rate for Seattle Genetics, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SGEN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SGEN are equal to 26.3%.

Life of production assets of 9.3 years is the average useful life of capital assets used in Seattle Genetics, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SGEN is equal to 2.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1273.943 million for Seattle Genetics, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 160.547 million for Seattle Genetics, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Seattle Genetics, Inc. at the current share price and the inputted number of shares is $11.0 billion.

RELATED COMPANIES Price Int.Val. Rating
ABBV AbbVie Inc. 78.69 31.53  str.sell
SPPI Spectrum Pharm 7.45 0.35  str.sell
CLDX Celldex Therap 2.48 1.52  str.sell
GSK GlaxoSmithKlin 40.12 65.66  str.buy
IMGN ImmunoGen, Inc 1.98 0.02  str.sell
BMY Bristol-Myers 47.56 78.06  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.